Document Type : CASE REPORT
Keywords
| 1. | |
| 2. | |
| 3. | |
| 4. | |
| 5. |
Heylen E, Scherer G, Vincent MF, Marie S, Fischer J, Nassogne MC. Tyrosinemia Type III detected via neonatal screening: Management and outcome. Mol Genet Metab 2012;107:605-7. ![]() [PUBMED] |
| 6. |
Lindstedt S, Holme E, Lock EA, Hjalmarson O, Strandvik B. Treatment of hereditary tyrosinaemia type I by inhibition of 4-hydroxyphenylpyruvate dioxygenase. Lancet 1992;340:813-7. ![]() [PUBMED] |
| 7. |
Nakamura K, Tanaka Y, Mitsubuchi H, Endo F. Animal models of tyrosinemia. J Nutr 2007;137:1556S-60. ![]() [PUBMED] |
| 8. |
Endo F, Kitano A, Uehara I, Nagata N, Matsuda I, Shinka T, et al. Four-hydroxyphenylpyruvic acid oxidase deficiency with normal fumarylacetoacetase: A new variant form of hereditary hypertyrosinemia. Pediatr Res 1983;17:92-6. ![]() [PUBMED] |
| 9. |
Awata H, Endo F, Matsuda I. Structure of the human 4-hydroxyphenylpyruvic acid dioxygenase gene (HPD). Genomics 1994;23:534-9. ![]() [PUBMED] |
| 10. | |
| 11. |
Ellaway CJ, Holme E, Standing S, Preece MA, Green A, Ploechl E, et al. Outcome of tyrosinaemia type III. J Inherit Metab Dis 2001;24:824-32. ![]() [PUBMED] |
| 12. | |
| 13. | |
| 14. | |
| 15. |